Advancing novel, small molecule treatments targeting epigenetic mechanisms in tumor and immune cells for the benefit of patients

Constellation Pharmaceuticals (NASDAQ: CNST) is a clinical-stage biopharmaceutical company developing novel small molecule therapies based on its pioneering research in cancer epigenetics. With a decade of experience in the field, the company has an unparalleled understanding of how epigenetic regulators modulate gene expression in cancer cells and in the tumor and immune microenvironment. Constellation is translating these insights to advance the company’s two lead clinical programs, CPI-1205 and CPI-0610, and in novel targets for which cancer epigenetics may help overcome resistance mechanisms to currently available treatment options.

Year Invested: 2008
Location: Cambridge, Mass.

Recent News

April 19, 2019
Constellation Pharmaceuticals to Present at the Solebury Trout Class of 2018 Biotech IPOs Investor Day

April 1, 2019
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting

March 14, 2019
Constellation Pharmaceuticals Announces Fourth-Quarter and Full-Year 2018 Financial Results

Read More News

Associated Team Members

Robert Tepper, M.D.

Neil Exter

Craig Muir
Partner/Chief Technology Officer